Citations (26)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (6)
Agnieszka Makowka & Michal Nowicki. (2021) Different Effect of Lanthanum Carbonate and Sevelamer Hydrochloride on Calcium Balance in Patients with Moderate to Advanced Chronic Kidney Disease. Therapeutics and Clinical Risk Management 17, pages 1145-1151.
Read now
Read now
Panagiotis Petrou. (2019) A systematic review of the economic evaluations of non-calcium-containing phosphate binders, sevelamer and Lanthanum, in end-stage renal disease patients with hyperphosphatemia. Expert Review of Pharmacoeconomics & Outcomes Research 19:3, pages 287-298.
Read now
Read now
J. Bover, P. Ureña-Torres, M. J. Lloret, C. Ruiz-García, I. DaSilva, M. M. Diaz-Encarnacion, C. Mercado, S. Mateu, E. Fernández & J. Ballarin. (2016) Integral pharmacological management of bone mineral disorders in chronic kidney disease (part I): from treatment of phosphate imbalance to control of PTH and prevention of progression of cardiovascular calcification. Expert Opinion on Pharmacotherapy 17:9, pages 1247-1258.
Read now
Read now
Shahrzad Ossareh. (2014) Clinical and economic aspects of sevelamer therapy in end-stage renal disease patients. International Journal of Nephrology and Renovascular Disease 7, pages 161-168.
Read now
Read now
Lisa Bernard, David Mendelssohn, Elizabeth Dunn, Colin Hutchison & Daniel T Grima. (2013) A modeled economic evaluation of sevelamer for treatment of hyperphosphatemia associated with chronic kidney disease among patients on dialysis in the United Kingdom. Journal of Medical Economics 16:1, pages 1-9.
Read now
Read now
Jacob Grinfeld, Akimichi Inaba & Alastair J Hutchison. (2010) Update and critical appraisal of sevelamer in the management of chronic renal failure. Open Access Journal of Urology 2, pages 161-170.
Read now
Read now
Articles from other publishers (20)
Kamolpat Chaiyakittisopon, Oraluck Pattanaprateep, Narisa Ruenroengbun, Tunlanut Sapankaew, Atiporn Ingsathit, Gareth J. Mckay, John Attia & Ammarin Thakkinstian. (2021) Evaluation of the cost-utility of phosphate binders as a treatment option for hyperphosphatemia in chronic kidney disease patients: a systematic review and meta-analysis of the economic evaluations. The European Journal of Health Economics 22:4, pages 571-584.
Crossref
Crossref
B. L. Goh, A. Soraya, A. Goh & K. L. Ang. (2018) Cost-Effectiveness Analysis for the Treatment of Hyperphosphatemia in Predialysis Patients: Calcium-Based versus Noncalcium-Based Phosphate Binders. International Journal of Nephrology 2018, pages 1-7.
Crossref
Crossref
Li Yang, Seng Chuen Tan, Can Chen, Xingzhi Wang, Xinya Li & Xiaoyan Yang. (2016) Economic Evaluation of Sevelamer versus Calcium-based Binders in Treating Hyperphosphatemia among Patients with End-stage Renal Disease in China. Clinical Therapeutics 38:11, pages 2459-2467.e1.
Crossref
Crossref
Rana Rizk, Mickaël Hiligsmann, Mirey Karavetian & Silvia MAA Evers. (2016) Economic evaluations of interventions to manage hyperphosphataemia in adult haemodialysis patients: A systematic review. Nephrology 21:3, pages 178-187.
Crossref
Crossref
Matteo Ruggeri, Antonio Bellasi, Filippo Cipriani, Donald Molony, Cynthia Bell, Domenico Russo & Biagio Di Iorio. (2014) Sevelamer is cost effective versus calcium carbonate for the first-line treatment of hyperphosphatemia in new patients to hemodialysis: a patient-level economic evaluation of the INDEPENDENT-HD study. Journal of Nephrology 28:5, pages 593-602.
Crossref
Crossref
Jessica C. Lloyd, Talitha Yen, Ricardo Pietrobon, John S. Wiener, Sherry S. Ross, Paul J. Kokorowski, Caleb P. Nelson & Jonathan C. Routh. (2014) Estimating utility values for vesicoureteral reflux in the general public using an online tool. Journal of Pediatric Urology 10:6, pages 1026-1031.
Crossref
Crossref
Michael S. Keith, Rosamund J. Wilson, Peter Preston & J. Brian Copley. (2014) Cost-Minimization Analysis of Lanthanum Carbonate Versus Sevelamer Hydrochloride in US Patients With End-stage Renal Disease. Clinical Therapeutics 36:9, pages 1276-1286.
Crossref
Crossref
Caroline M. Perry & Greg L. Plosker. (2014) Sevelamer Carbonate: A Review in Hyperphosphataemia in Adults with Chronic Kidney Disease. Drugs 74:7, pages 771-792.
Crossref
Crossref
Antonio Bellasi & Biagio Raffaele Di Iorio. (2014) Phosphate Metabolism Modulation in Chronic Kidney Disease: When, How and to What Extent?. Nephro-Urology Monthly 6:3.
Crossref
Crossref
Shunsuke Goto, Hirotaka Komaba, Masafumi Fukagawa & Shinichi Nishi. (2013) Optimizing the cost-effectiveness of treatment for chronic kidney disease-mineral and bone disorder. Kidney International Supplements 3:5, pages 457-461.
Crossref
Crossref
Aurélie Lenglet, Sophie Liabeuf, Pauline Guffroy, Albert Fournier, Michel Brazier & Ziad A. Massy. (2013) Use of Nicotinamide to Treat Hyperphosphatemia in Dialysis Patients. Drugs in R&D 13:3, pages 165-173.
Crossref
Crossref
Sudha P. Chennasamudram, Tanjila Noor & Tetyana L. Vasylyeva. (2013) COMPARISON OF SEVELAMER AND CALCIUM CARBONATE ON ENDOTHELIAL FUNCTION AND INFLAMMATION IN PATIENTS ON PERITONEAL DIALYSIS. Journal of Renal Care 39:2, pages 82-89.
Crossref
Crossref
Daniel T. Grima, Lisa M. Bernard, Elizabeth S. Dunn, Philip A. McFarlane & David C. Mendelssohn. (2012) Cost-Effectiveness Analysis of Therapies for Chronic Kidney Disease Patients on Dialysis. PharmacoEconomics 30:11, pages 981-989.
Crossref
Crossref
Mario Cozzolino, Maria Antonietta Rizzo, Andrea Stucchi, Daniele Cusi & Maurizio Gallieni. (2012) Sevelamer for hyperphosphataemia in kidney failure: controversy and perspective. Therapeutic Advances in Chronic Disease 3:2, pages 59-68.
Crossref
Crossref
Haesuk Park, Karen L. Rascati, Michael S. Keith, Paul Hodgkins, Michael Smyth, David Goldsmith & Ron Akehurst. (2011) Cost-Effectiveness of Lanthanum Carbonate versus Sevelamer Hydrochloride for the Treatment of Hyperphosphatemia in Patients with End-Stage Renal Disease: A US Payer Perspective. Value in Health 14:8, pages 1002-1009.
Crossref
Crossref
Sankar D Navaneethan, Suetonia C Palmer, Mariacristina Vecchio, Jonathan C Craig, Grahame J Elder & Giovanni FM Strippoli. (2011) Phosphate binders for preventing and treating bone disease in chronic kidney disease patients. Cochrane Database of Systematic Reviews.
Crossref
Crossref
Jonathan C. Routh, Marc R. Laufer, Glenn M. Cannon, David A. Diamond & Patricio C. Gargollo. (2010) Management Strategies for Mayer-Rokitansky-Kuster-Hauser Related Vaginal Agenesis: A Cost-Effectiveness Analysis. Journal of Urology 184:5, pages 2116-2122.
Crossref
Crossref
Hirotaka Komaba, Kensuke Moriwaki, Isao Kamae & Masafumi Fukagawa. (2009) Towards Cost-effective Strategies for Treatment of Chronic Kidney Disease-Mineral and Bone Disorder in Japan. Therapeutic Apheresis and Dialysis 13, pages S28-S35.
Crossref
Crossref
Sankar D. Navaneethan, Suetonia C. Palmer, Jonathan C. Craig, Grahame J. Elder & Giovanni F.M. Strippoli. (2009) Benefits and Harms of Phosphate Binders in CKD: A Systematic Review of Randomized Controlled Trials. American Journal of Kidney Diseases 54:4, pages 619-637.
Crossref
Crossref
. (2013) Sevelamer could be worth it in hyperphosphataemia. PharmacoEconomics & Outcomes News 552:1, pages 3-3.
Crossref
Crossref